NMO Drug Looks Good for IgG4-Related Disease

(MedPage Today) -- WASHINGTON -- Patients with IgG4-related disease appeared to benefit from inebilizumab (Uplizna), currently approved for neuromyelitis optica (NMO), in a pivotal clinical trial.
Just 10% of patients treated with the drug in...